Permanent coronary drug-eluting stents

Current status

Following a 2022 procurement process, Boston became the major supplier of permanent coronary drug-eluting stents to Health NZ | Te Whatu Ora hospitals from 1 March 2023 until 28 February 2026. This meant:

• Boston became the major supplier of permanent coronary drug-eluting stents and has Principal Supply Status (PSS).
• At least 65% of the permanent coronary drug-eluting stents used in Health NZ hospitals must be purchased from Boston.
• The remaining 35% can be bought from other suppliers of permanent coronary drug-eluting stents (this is the Alternative Brand Allowance).

Return to market 

With the current PSS awarded to Boston Scientific set to expire on 28 February 2026, Pharmac is seeking proposals for the ongoing supply of drug-eluting stents in Health NZ hospitals.  

Our previous clinical advice from the Interventional Cardiology Advisory Group supported a preference for the 65% market share model, with a 35% alternative brand allowance. Our data on hospital compliance to the 65% model supports this approach. As such, we're approaching the market with the same 65% market share model. 

What would this mean for patients?

There would be no change for patients who already have a permanent coronary drug-eluting stent. Suitable treatment options will continue to be available for patients nationwide. The 35% Alternative Brand Allowance would allow Te Whatu Ora hospitals to continue to treat patients with another permanent coronary drug-eluting stent when necessary.

Staying in touch

If you have any questions or would like to be kept up to date, please contact us at enquiry@pharmac.govt.nz, phone 0800 660 050, or sign up to receive our regular newsletter update Device Advice.